The NHS has announced its intention to introduce a new drug, Osimertinib, following positive trials with lung cancer patients.
It will be used with patients suffering from a specific early-stage non-small cell lung cancer and could halve the risk of the disease returning.
According to the NHS, trials of the drug showed a significant increase in the number of patients who remained disease-free after two years.
The roll-out of the drug, the first to address this particular form of lung cancer, is planned to start later this year for suitable patients following surgery.
The NHS is committed to trying to improve detection of lung cancer and reduce the impact of this deadly disease. It has recently been trying to raise awareness amongst the general public of the early symptoms of lung cancer.
Legal advice
If you or a loved one are struggling with the impact of a significant failing in medical care, contact Glynns Solicitors to talk to a medical negligence compensation specialist.
Please call us on 0800 234 3300 (or from a mobile 01275 334030) or complete our Online Enquiry Form.
Share Article With:
|
|
|
|
|
|
